1 Market Overview
1.1 Antibody-drug Conjugates Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Antibody-drug Conjugates Revenue by Type: 2020 Versus 2024 Versus 2031
1.2.2 Adcetris
1.2.3 Kadcyla
1.3 Market Analysis by Application
1.3.1 Overview: Global Antibody-drug Conjugates Revenue by Application: 2020 Versus 2024 Versus 2031
1.3.2 Breast Cancer
1.3.3 Lymphoma
1.4 Global Antibody-drug Conjugates Market Size & Forecast
1.4.1 Global Antibody-drug Conjugates Sales in Value (2020 & 2024 & 2031)
1.4.2 Global Antibody-drug Conjugates Sales in Volume (2020-2031)
1.4.3 Global Antibody-drug Conjugates Price (2020-2031)
1.5 Global Antibody-drug Conjugates Production Capacity Analysis
1.5.1 Global Antibody-drug Conjugates Total Production Capacity (2020-2031)
1.5.2 Global Antibody-drug Conjugates Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Antibody-drug Conjugates Market Drivers
1.6.2 Antibody-drug Conjugates Market Restraints
1.6.3 Antibody-drug Conjugates Trends Analysis
2 Manufacturers Profiles
2.1 ImmunoGen
2.1.1 ImmunoGen Details
2.1.2 ImmunoGen Major Business
2.1.3 ImmunoGen Antibody-drug Conjugates Product and Services
2.1.4 ImmunoGen Antibody-drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.2 Seattle Genetics
2.2.1 Seattle Genetics Details
2.2.2 Seattle Genetics Major Business
2.2.3 Seattle Genetics Antibody-drug Conjugates Product and Services
2.2.4 Seattle Genetics Antibody-drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Antibody-drug Conjugates Product and Services
2.3.4 Roche Antibody-drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.4 Takeda
2.4.1 Takeda Details
2.4.2 Takeda Major Business
2.4.3 Takeda Antibody-drug Conjugates Product and Services
2.4.4 Takeda Antibody-drug Conjugates Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
3 Antibody-drug Conjugates Breakdown Data by Manufacturer
3.1 Global Antibody-drug Conjugates Sales in Volume by Manufacturer (2021, 2022, 2023, and 2024)
3.2 Global Antibody-drug Conjugates Revenue by Manufacturer (2021, 2022, 2023, and 2024)
3.3 Key Manufacturer Market Position in Antibody-drug Conjugates
3.4 Market Concentration Rate
3.4.1 Top 3 Antibody-drug Conjugates Manufacturer Market Share in 2024
3.4.2 Top 6 Antibody-drug Conjugates Manufacturer Market Share in 2024
3.5 Global Antibody-drug Conjugates Production Capacity by Company: 2023 VS 2024
3.6 Manufacturer by Geography: Head Office and Antibody-drug Conjugates Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Antibody-drug Conjugates Market Size by Region
4.1.1 Global Antibody-drug Conjugates Sales in Volume by Region (2020-2031)
4.1.2 Global Antibody-drug Conjugates Revenue by Region (2020-2031)
4.2 North America Antibody-drug Conjugates Revenue (2020-2031)
4.3 Europe Antibody-drug Conjugates Revenue (2020-2031)
4.4 Asia-Pacific Antibody-drug Conjugates Revenue (2020-2031)
4.5 South America Antibody-drug Conjugates Revenue (2020-2031)
4.6 Middle East and Africa Antibody-drug Conjugates Revenue (2020-2031)
5 Market Segment by Type
5.1 Global Antibody-drug Conjugates Sales in Volume by Type (2020-2031)
5.2 Global Antibody-drug Conjugates Revenue by Type (2020-2031)
5.3 Global Antibody-drug Conjugates Price by Type (2020-2031)
6 Market Segment by Application
6.1 Global Antibody-drug Conjugates Sales in Volume by Application (2020-2031)
6.2 Global Antibody-drug Conjugates Revenue by Application (2020-2031)
6.3 Global Antibody-drug Conjugates Price by Application (2020-2031)
7 North America by Country, by Type, and by Application
7.1 North America Antibody-drug Conjugates Sales by Type (2020-2031)
7.2 North America Antibody-drug Conjugates Sales by Application (2020-2031)
7.3 North America Antibody-drug Conjugates Market Size by Country
7.3.1 North America Antibody-drug Conjugates Sales in Volume by Country (2020-2031)
7.3.2 North America Antibody-drug Conjugates Revenue by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 Europe by Country, by Type, and by Application
8.1 Europe Antibody-drug Conjugates Sales by Type (2020-2031)
8.2 Europe Antibody-drug Conjugates Sales by Application (2020-2031)
8.3 Europe Antibody-drug Conjugates Market Size by Country
8.3.1 Europe Antibody-drug Conjugates Sales in Volume by Country (2020-2031)
8.3.2 Europe Antibody-drug Conjugates Revenue by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Antibody-drug Conjugates Sales by Type (2020-2031)
9.2 Asia-Pacific Antibody-drug Conjugates Sales by Application (2020-2031)
9.3 Asia-Pacific Antibody-drug Conjugates Market Size by Region
9.3.1 Asia-Pacific Antibody-drug Conjugates Sales in Volume by Region (2020-2031)
9.3.2 Asia-Pacific Antibody-drug Conjugates Revenue by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 South America by Region, by Type, and by Application
10.1 South America Antibody-drug Conjugates Sales by Type (2020-2031)
10.2 South America Antibody-drug Conjugates Sales by Application (2020-2031)
10.3 South America Antibody-drug Conjugates Market Size by Country
10.3.1 South America Antibody-drug Conjugates Sales in Volume by Country (2020-2031)
10.3.2 South America Antibody-drug Conjugates Revenue by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Antibody-drug Conjugates Sales by Type (2020-2031)
11.2 Middle East & Africa Antibody-drug Conjugates Sales by Application (2020-2031)
11.3 Middle East & Africa Antibody-drug Conjugates Market Size by Country
11.3.1 Middle East & Africa Antibody-drug Conjugates Sales in Volume by Country (2020-2031)
11.3.2 Middle East & Africa Antibody-drug Conjugates Revenue by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 Raw Material and Industry Chain
12.1 Raw Material of Antibody-drug Conjugates and Key Manufacturers
12.2 Manufacturing Costs Percentage of Antibody-drug Conjugates
12.3 Antibody-drug Conjugates Production Process
12.4 Antibody-drug Conjugates Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Antibody-drug Conjugates Typical Distributors
13.3 Antibody-drug Conjugates Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Antibody-drug Conjugates Revenue by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Antibody-drug Conjugates Revenue by Application, (USD Million), 2020 & 2024 & 2031
Table 3. ImmunoGen Basic Information, Manufacturing Base and Competitors
Table 4. ImmunoGen Major Business
Table 5. ImmunoGen Antibody-drug Conjugates Product and Services
Table 6. ImmunoGen Antibody-drug Conjugates Sales (Kg), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 7. Seattle Genetics Basic Information, Manufacturing Base and Competitors
Table 8. Seattle Genetics Major Business
Table 9. Seattle Genetics Antibody-drug Conjugates Product and Services
Table 10. Seattle Genetics Antibody-drug Conjugates Sales (Kg), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 11. Roche Basic Information, Manufacturing Base and Competitors
Table 12. Roche Major Business
Table 13. Roche Antibody-drug Conjugates Product and Services
Table 14. Roche Antibody-drug Conjugates Sales (Kg), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 15. Takeda Basic Information, Manufacturing Base and Competitors
Table 16. Takeda Major Business
Table 17. Takeda Antibody-drug Conjugates Product and Services
Table 18. Takeda Antibody-drug Conjugates Sales (Kg), Price (USD/Kg), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 19. Global Antibody-drug Conjugates Sales by Manufacturer (2021, 2022, 2023, and 2024) & (Kg)
Table 20. Global Antibody-drug Conjugates Revenue by Manufacturer (2021, 2022, 2023, and 2024) & (USD Million)
Table 21. Market Position of Manufacturers in Antibody-drug Conjugates, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 22. Global Antibody-drug Conjugates Production Capacity by Company, (Kg): 2023 VS 2024
Table 23. Head Office and Antibody-drug Conjugates Production Site of Key Manufacturer
Table 24. Antibody-drug Conjugates New Entrant and Capacity Expansion Plans
Table 25. Antibody-drug Conjugates Mergers & Acquisitions in the Past Five Years
Table 26. Global Antibody-drug Conjugates Sales by Region (2020-2024) & (Kg)
Table 27. Global Antibody-drug Conjugates Sales by Region (2025-2031) & (Kg)
Table 28. Global Antibody-drug Conjugates Revenue by Region (2020-2024) & (USD Million)
Table 29. Global Antibody-drug Conjugates Revenue by Region (2025-2031) & (USD Million)
Table 30. Global Antibody-drug Conjugates Sales by Type (2020-2024) & (Kg)
Table 31. Global Antibody-drug Conjugates Sales by Type (2025-2031) & (Kg)
Table 32. Global Antibody-drug Conjugates Revenue by Type (2020-2024) & (USD Million)
Table 33. Global Antibody-drug Conjugates Revenue by Type (2025-2031) & (USD Million)
Table 34. Global Antibody-drug Conjugates Price by Type (2020-2024) & (USD/Kg)
Table 35. Global Antibody-drug Conjugates Price by Type (2025-2031) & (USD/Kg)
Table 36. Global Antibody-drug Conjugates Sales by Application (2020-2024) & (Kg)
Table 37. Global Antibody-drug Conjugates Sales by Application (2025-2031) & (Kg)
Table 38. Global Antibody-drug Conjugates Revenue by Application (2020-2024) & (USD Million)
Table 39. Global Antibody-drug Conjugates Revenue by Application (2025-2031) & (USD Million)
Table 40. Global Antibody-drug Conjugates Price by Application (2020-2024) & (USD/Kg)
Table 41. Global Antibody-drug Conjugates Price by Application (2025-2031) & (USD/Kg)
Table 42. North America Antibody-drug Conjugates Sales by Country (2020-2024) & (Kg)
Table 43. North America Antibody-drug Conjugates Sales by Country (2025-2031) & (Kg)
Table 44. North America Antibody-drug Conjugates Revenue by Country (2020-2024) & (USD Million)
Table 45. North America Antibody-drug Conjugates Revenue by Country (2025-2031) & (USD Million)
Table 46. North America Antibody-drug Conjugates Sales by Type (2020-2024) & (Kg)
Table 47. North America Antibody-drug Conjugates Sales by Type (2025-2031) & (Kg)
Table 48. North America Antibody-drug Conjugates Sales by Application (2020-2024) & (Kg)
Table 49. North America Antibody-drug Conjugates Sales by Application (2025-2031) & (Kg)
Table 50. Europe Antibody-drug Conjugates Sales by Country (2020-2024) & (Kg)
Table 51. Europe Antibody-drug Conjugates Sales by Country (2025-2031) & (Kg)
Table 52. Europe Antibody-drug Conjugates Revenue by Country (2020-2024) & (USD Million)
Table 53. Europe Antibody-drug Conjugates Revenue by Country (2025-2031) & (USD Million)
Table 54. Europe Antibody-drug Conjugates Sales by Type (2020-2024) & (Kg)
Table 55. Europe Antibody-drug Conjugates Sales by Type (2025-2031) & (Kg)
Table 56. Europe Antibody-drug Conjugates Sales by Application (2020-2024) & (Kg)
Table 57. Europe Antibody-drug Conjugates Sales by Application (2025-2031) & (Kg)
Table 58. Asia-Pacific Antibody-drug Conjugates Sales by Region (2020-2024) & (Kg)
Table 59. Asia-Pacific Antibody-drug Conjugates Sales by Region (2025-2031) & (Kg)
Table 60. Asia-Pacific Antibody-drug Conjugates Revenue by Region (2020-2024) & (USD Million)
Table 61. Asia-Pacific Antibody-drug Conjugates Revenue by Region (2025-2031) & (USD Million)
Table 62. Asia-Pacific Antibody-drug Conjugates Sales by Type (2020-2024) & (Kg)
Table 63. Asia-Pacific Antibody-drug Conjugates Sales by Type (2025-2031) & (Kg)
Table 64. Asia-Pacific Antibody-drug Conjugates Sales by Application (2020-2024) & (Kg)
Table 65. Asia-Pacific Antibody-drug Conjugates Sales by Application (2025-2031) & (Kg)
Table 66. South America Antibody-drug Conjugates Sales by Country (2020-2024) & (Kg)
Table 67. South America Antibody-drug Conjugates Sales by Country (2025-2031) & (Kg)
Table 68. South America Antibody-drug Conjugates Revenue by Country (2020-2024) & (USD Million)
Table 69. South America Antibody-drug Conjugates Revenue by Country (2025-2031) & (USD Million)
Table 70. South America Antibody-drug Conjugates Sales by Type (2020-2024) & (Kg)
Table 71. South America Antibody-drug Conjugates Sales by Type (2025-2031) & (Kg)
Table 72. South America Antibody-drug Conjugates Sales by Application (2020-2024) & (Kg)
Table 73. South America Antibody-drug Conjugates Sales by Application (2025-2031) & (Kg)
Table 74. Middle East & Africa Antibody-drug Conjugates Sales by Region (2020-2024) & (Kg)
Table 75. Middle East & Africa Antibody-drug Conjugates Sales by Region (2025-2031) & (Kg)
Table 76. Middle East & Africa Antibody-drug Conjugates Revenue by Region (2020-2024) & (USD Million)
Table 77. Middle East & Africa Antibody-drug Conjugates Revenue by Region (2025-2031) & (USD Million)
Table 78. Middle East & Africa Antibody-drug Conjugates Sales by Type (2020-2024) & (Kg)
Table 79. Middle East & Africa Antibody-drug Conjugates Sales by Type (2025-2031) & (Kg)
Table 80. Middle East & Africa Antibody-drug Conjugates Sales by Application (2020-2024) & (Kg)
Table 81. Middle East & Africa Antibody-drug Conjugates Sales by Application (2025-2031) & (Kg)
Table 82. Antibody-drug Conjugates Raw Material
Table 83. Key Manufacturers of Antibody-drug Conjugates Raw Materials
Table 84. Direct Channel Pros & Cons
Table 85. Indirect Channel Pros & Cons
Table 86. Antibody-drug Conjugates Typical Distributors
Table 87. Antibody-drug Conjugates Typical Customers
List of Figures
Figure 1. Antibody-drug Conjugates Picture
Figure 2. Global Antibody-drug Conjugates Revenue Market Share by Type in 2024
Figure 3. Adcetris
Figure 4. Kadcyla
Figure 5. Global Antibody-drug Conjugates Revenue Market Share by Application in 2024
Figure 6. Breast Cancer
Figure 7. Lymphoma
Figure 8. Global Antibody-drug Conjugates Revenue, (USD Million) & (Kg): 2020 & 2024 & 2031
Figure 9. Global Antibody-drug Conjugates Revenue and Forecast (2020-2031) & (USD Million)
Figure 10. Global Antibody-drug Conjugates Sales (2020-2031) & (Kg)
Figure 11. Global Antibody-drug Conjugates Price (2020-2031) & (USD/Kg)
Figure 12. Global Antibody-drug Conjugates Production Capacity (2020-2031) & (Kg)
Figure 13. Global Antibody-drug Conjugates Production Capacity by Geographic Region: 2024 VS 2031
Figure 14. Antibody-drug Conjugates Market Drivers
Figure 15. Antibody-drug Conjugates Market Restraints
Figure 16. Antibody-drug Conjugates Market Trends
Figure 17. Global Antibody-drug Conjugates Sales Market Share by Manufacturer in 2024
Figure 18. Global Antibody-drug Conjugates Revenue Market Share by Manufacturer in 2024
Figure 19. Antibody-drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 20. Top 3 Antibody-drug Conjugates Manufacturer (Revenue) Market Share in 2024
Figure 21. Top 6 Antibody-drug Conjugates Manufacturer (Revenue) Market Share in 2024
Figure 22. Global Antibody-drug Conjugates Sales Market Share by Region (2020-2031)
Figure 23. Global Antibody-drug Conjugates Revenue Market Share by Region (2020-2031)
Figure 24. North America Antibody-drug Conjugates Revenue (2020-2031) & (USD Million)
Figure 25. Europe Antibody-drug Conjugates Revenue (2020-2031) & (USD Million)
Figure 26. Asia-Pacific Antibody-drug Conjugates Revenue (2020-2031) & (USD Million)
Figure 27. South America Antibody-drug Conjugates Revenue (2020-2031) & (USD Million)
Figure 28. Middle East & Africa Antibody-drug Conjugates Revenue (2020-2031) & (USD Million)
Figure 29. Global Antibody-drug Conjugates Sales Market Share by Type (2020-2031)
Figure 30. Global Antibody-drug Conjugates Revenue Market Share by Type (2020-2031)
Figure 31. Global Antibody-drug Conjugates Price by Type (2020-2031) & (USD/Kg)
Figure 32. Global Antibody-drug Conjugates Sales Market Share by Application (2020-2031)
Figure 33. Global Antibody-drug Conjugates Revenue Market Share by Application (2020-2031)
Figure 34. Global Antibody-drug Conjugates Price by Application (2020-2031) & (USD/Kg)
Figure 35. North America Antibody-drug Conjugates Sales Market Share by Type (2020-2031)
Figure 36. North America Antibody-drug Conjugates Sales Market Share by Application (2020-2031)
Figure 37. North America Antibody-drug Conjugates Sales Market Share by Country (2020-2031)
Figure 38. North America Antibody-drug Conjugates Revenue Market Share by Country (2020-2031)
Figure 39. United States Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 40. Canada Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 41. Mexico Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 42. Europe Antibody-drug Conjugates Sales Market Share by Type (2020-2031)
Figure 43. Europe Antibody-drug Conjugates Sales Market Share by Application (2020-2031)
Figure 44. Europe Antibody-drug Conjugates Sales Market Share by Country (2020-2031)
Figure 45. Europe Antibody-drug Conjugates Revenue Market Share by Country (2020-2031)
Figure 46. Germany Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 47. France Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 48. United Kingdom Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 49. Russia Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 50. Italy Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 51. Asia-Pacific Antibody-drug Conjugates Sales Market Share by Region (2020-2031)
Figure 52. Asia-Pacific Antibody-drug Conjugates Sales Market Share by Application (2020-2031)
Figure 53. Asia-Pacific Antibody-drug Conjugates Sales Market Share by Region (2020-2031)
Figure 54. Asia-Pacific Antibody-drug Conjugates Revenue Market Share by Region (2020-2031)
Figure 55. China Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 56. Japan Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 57. Korea Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 58. India Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 59. Southeast Asia Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 60. Australia Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 61. South America Antibody-drug Conjugates Sales Market Share by Type (2020-2031)
Figure 62. South America Antibody-drug Conjugates Sales Market Share by Application (2020-2031)
Figure 63. South America Antibody-drug Conjugates Sales Market Share by Country (2020-2031)
Figure 64. South America Antibody-drug Conjugates Revenue Market Share by Country (2020-2031)
Figure 65. Brazil Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 66. Argentina Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 67. Middle East & Africa Antibody-drug Conjugates Sales Market Share by Type (2020-2031)
Figure 68. Middle East & Africa Antibody-drug Conjugates Sales Market Share by Application (2020-2031)
Figure 69. Middle East & Africa Antibody-drug Conjugates Sales Market Share by Region (2020-2031)
Figure 70. Middle East & Africa Antibody-drug Conjugates Revenue Market Share by Region (2020-2031)
Figure 71. Turkey Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 72. Egypt Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 73. Saudi Arabia Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 74. South Africa Antibody-drug Conjugates Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Antibody-drug Conjugates in 2024
Figure 76. Manufacturing Process Analysis of Antibody-drug Conjugates
Figure 77. Antibody-drug Conjugates Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source
※参考情報 抗体薬物複合体(Antibody-drug Conjugates、ADC)は、がん治療において新しいアプローチとして注目される治療法の一つです。抗体と細胞毒性薬物を結合させたこの複合体は、特定の標的細胞に対して選択的に作用し、正常細胞への影響を最小限に抑えることができることから、治療の効果を高める可能性があります。 まず、抗体薬物複合体の定義について説明します。ADCは、モノクローナル抗体(特定の抗原に対して特異的に結合する抗体)と細胞毒性薬物(がん細胞に対して致死的な効果を持つ化学薬品)を連結した分子です。抗体は、がん細胞の表面に存在する特定の抗原に結合し、その後、細胞内に取り込まれます。取り込まれた抗体は、内部の細胞毒性薬物を放出し、がん細胞を死に至らしめるという仕組みです。 ADCの特徴として、まず挙げられるのは、選択性の高さです。抗体は標的細胞に対する特異性を持つため、正常な細胞に対する毒性を抑えることができます。これにより、副作用が軽減され、患者のQOL(生活の質)が向上することが期待されます。また、抗体薬物複合体は、従来の化学療法に比べて新たな治療の道を開くことになり、より効率的にがん細胞を攻撃することができます。 抗体薬物複合体の種類は、使用される抗体の種類や薬物の特性に応じて多岐にわたります。まず、抗体としては、慢性リンパ性白血病(CLL)やホジキンリンパ腫などに用いられるリツキシマブ(Rituximab)や、乳がんや肺がんに対するトラストズマブ(Trastuzumab)などがあります。さらに、細胞毒性薬物には、微小管阻害剤、DNA合成抑制剤、抗生物質など様々な種類があります。これにより、それぞれのがんの特性に応じたアプローチが可能になります。 ADCの用途については、主に悪性腫瘍における治療として利用されています。特に、再発や転移を伴うがんに対して、従来の治療法では効果が限定的な場合が多く、ADCの導入によって新たな治療の可能性が開けます。現在でも、既に多くのADCが臨床試験を経て承認され、実際の治療に用いられています。 関連技術としては、抗体や薬物の結合技術や、複合体の安定性を向上させるための修飾技術が挙げられます。また、新しい標的を見つけるためのバイオマーカー研究や、抗体の改良、さらに薬物放出の制御技術なども、ADCのさらなる進化を支える重要な技術です。最近では、ナノテクノロジーを利用した薬物運搬システムや、遺伝子工学技術を用いた抗体設計が進展しており、ADCの安全性や効果を高める研究が進められています。 抗体薬物複合体の臨床的な成功例として、アステラス製薬のアドトリフツマブ(Adotrastuzumab emtansine)や、セリバス製薬のイファチニブ(Droghed Gikd)などが挙げられます。これらの製品は、特定のがんにおいて高い効果を示し、治療選択肢として評価されています。しかし、依然として多くのがんに対して効果が限定的であるため、さらなる研究と改良が求められています。 現在、抗体薬物複合体は、その選択的な作用と限られた副作用から、がん治療において非常に魅力的な選択肢とされています。今後の研究によって、より多くの適応症に対する治療法が確立されることが期待されており、がん治療の新たなパラダイムシフトが起こる可能性があります。抗体薬物複合体の今後の展望としては、より多様な抗原に対する抗体の開発や、薬物の選択肢を広げること、新たな結合技術の実用化が挙げられます。 以上の理由から、抗体薬物複合体は、がん治療の未来に向けて非常に重要な技術であり、その発展が期待されています。これからの研究や臨床応用により、より多くの患者が恩恵を受けることが可能となるでしょう。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/